TABLE 3.
Conversion and cumulative prevalence rates
| Latino CHR subjects (N = 39)
|
Non-Latino CHR subjects (N = 252)
|
All CHR subjects (N = 291)
|
||||
|---|---|---|---|---|---|---|
| Total converters | Cumulative prevalence rates (%) | Total converters | Cumulative prevalence rates (%) | Total converters | Cumulative prevalence rates (%) | |
| 6 months | 5 | 12.8 | 37 | 14.7 | 42 | 12.7 |
| 12 months | 8 | 20.5 | 53 | 26.6 | 61 | 21.7 |
| 18 months | 12 | 30.8 | 60 | 31.3 | 72 | 26.8 |
| 24 months | 14 | 35.9 | 65 | 34.4 | 79 | 32.6 |
| 30 months | 15 | 38.5 | 67 | 36.2 | 82 | 35.3 |
CHR, clinical high risk.